Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 369 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Transplant; Failure, Kidney Clear all
Active, not recruiting Phase 1 Interventional

Immunological Tolerance in Patients With Mismatched Kidney Transplants

NCT05806749
View directory record Official record
Conditions
End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions
Donor CD34+, CD3+. and belumosudil
Combination Product
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional

Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis

NCT02981706
View directory record Official record
Conditions
Chronic Kidney Disease, Endstage Renal Disease
Interventions
Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
Procedure
Lead sponsor
Columbia University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Nov 10, 2026, 5:48 PM EST
Not yet recruiting Not applicable Interventional

Technology-enabled Social Network Intervention to Increase Live Donor Kidney Transplantation

NCT07072767
View directory record Official record
Conditions
End-Stage Renal Disease, Chronic Kidney Diseases, Kidney Transplant, Living Kidney Donor
Interventions
Digital education outreach intervention for kidney transplant access and human guide, Digital education outreach intervention for kidney transplant access only (unguided)
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Low Dose Thymoglobin in Renal Transplant Patients

NCT01280617
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Thymoglobulin, Thymoglobulin 0.75mg/kg dose
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional

Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge

NCT02268682
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Patient-Guided, Educator-Guided
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 74 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Nov 10, 2026, 5:48 PM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants

NCT06741072
View directory record Official record
Conditions
Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions
Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21
Procedure · Drug · Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Enrolling by invitation No phase listed Observational

Renal Allograft Fibrosis Study

NCT05058170
View directory record Official record
Conditions
Renal Allograft Fibrosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium

NCT01680861
View directory record Official record
Conditions
Transplant; Failure, Kidney
Interventions
Tacrolimus, Everolimus, Enteric Coated Mycophenolate Sodium (EC-MPS), Corticosteroids
Drug
Lead sponsor
Gaetano Ciancio
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Nov 10, 2026, 5:48 PM EST
Active, not recruiting No phase listed Observational

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

NCT03615235
View directory record Official record
Conditions
Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Not applicable Interventional Results available

Propaten Randomized Investigation on Cost-benefit and Efficacy

NCT01601873
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
PROPATEN, Standard Graft
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • New Orleans, Louisiana • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

NCT00765661
View directory record Official record
Conditions
Kidney Failure, Renal Failure
Interventions
Tacrolimus (Tacro™), Prograf
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Not applicable Interventional

Randomized Fistula Study

NCT00808561
View directory record Official record
Conditions
Renal Failure
Interventions
Group 1: Alternative Fistula, Group 2: Forearm AV Graft
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Nov 10, 2026, 5:48 PM EST
No Longer Available No phase listed Expanded access

Islet Transplant for Type 1 or Surgical Diabetes

NCT01606475
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypoglycemia, Labile Diabetes, End-stage Renal Disease
Interventions
Allogeneic islets of Langerhans
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Recruiting Not applicable Interventional

Deceased Donor Kidney Storage at 10 Celsius Versus Conventional Storage

NCT07385651
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Chronic Kidney Disease (Stages 4 and 5), Kidney Transplantation Recipients
Interventions
10˚C deceased donor kidney storage using Traferox XPort
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Recruiting Phase 1Phase 2 Interventional

Breakthrough - T1DM and Chronic Kidney Disease

NCT07592000
View directory record Official record
Conditions
Diabete Type 1, Chronic Kidney Disease
Interventions
Tegoprubart, Islet Cell Transplant
Drug · Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Miami, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Recruiting Phase 3 Interventional

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

NCT03394365
View directory record Official record
Conditions
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions
tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2 Interventional Results available

Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome

NCT01029587
View directory record Official record
Conditions
Antiphospholipid Antibody Syndrome, End Stage Renal Disease
Interventions
Eculizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Phase 2 Interventional

Safety, Tolerability and Pharmacodynamics of AP214 Acetate in Patients Undergoing Cardiac Surgery

NCT00628264
View directory record Official record
Conditions
Cardiac Surgery, Coronary Artery Bypass Grafting, Valve Surgery, Kidney Injury
Interventions
AP214, Placebo
Drug
Lead sponsor
Action Pharma A/S
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2009 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2Phase 3 Interventional

Myfortic vs. Cellcept in Kidney Transplant Recipients

NCT00533624
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Mycophenolate Sodium Delayed Release Tablets, Mycophenolate Mofetil
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Nov 10, 2026, 5:48 PM EST
Terminated Phase 2 Interventional Results available

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

NCT00986947
View directory record Official record
Conditions
Kidney Failure
Interventions
IVIg and rituximab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 3 Interventional Results available

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx

NCT01187953
View directory record Official record
Conditions
Renal Failure
Interventions
Prograf (tacrolimus), LCP-Tacro
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Nov 10, 2026, 5:48 PM EST
Completed Phase 2Phase 3 Interventional Results available

Efficacy of Sirolimus-Based, Steroid Avoidance Immunosuppression African Americans

NCT00189202
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplantation
Interventions
Sirolimus
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Nov 10, 2026, 5:48 PM EST
Completed Not applicable Interventional Results available

Disparities in National Kidney Allocation Policy

NCT02879812
View directory record Official record
Conditions
Kidney Disorders
Interventions
Performance Feedback Reports, Educational Video for Staff, Educational Video for Patients, Educational Webinar, Standard Care, United Network for Organ Sharing (UNOS) Pamphlet
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
56,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Nov 10, 2026, 5:48 PM EST
Not listed No phase listed Observational

Morbidity and Mortality Among Dialysis Patients After Treatment for Depression

NCT00442429
View directory record Official record
Conditions
Depression, ESRD
Interventions
Not listed
Lead sponsor
Portland VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 2, 2007 · Synced Nov 10, 2026, 5:48 PM EST